Ascletis Pharma (OTCMKTS:ASCLF) Trading Up 26.6% – Still a Buy?

Ascletis Pharma Inc. (OTCMKTS:ASCLFGet Free Report)’s share price shot up 26.6% during mid-day trading on Thursday . The company traded as high as $1.45 and last traded at $1.45. 10,000 shares were traded during trading, an increase of 329% from the average session volume of 2,329 shares. The stock had previously closed at $1.1450.

Ascletis Pharma Stock Performance

The company’s 50-day simple moving average is $1.32 and its 200 day simple moving average is $1.25.

About Ascletis Pharma

(Get Free Report)

Ascletis Pharma Inc, a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.

Featured Stories

Receive News & Ratings for Ascletis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascletis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.